Desmopressin in a long-term treatment of children with primary nocturnal enuresis - a symptomatic therapy?

Abstract

Desmopressin (DDAVP) has been successfully used in the therapy of primary monosymptomatic nocturnal enuresis PNE)[3+-6]. Recently Alon has shown that prolonged use of DDAVP improves the results and decreases the relapse rate after withdrawal of therapy.

The spontaneous cure rate has been approximately 15% per year. We determined the efficacy and safety of long-term treatment with DDAVP in children with PNE.

Keywords

• Desmopressin
• symptomatic therapy